ライフサイエンスコーパス: early therapy

1 infected individuals who were all started on early therapy.

2 han 12 months) may also receive benefit from early therapy.

3 n ganciclovir is given for prophylaxis or as early therapy.

4 ttle is known about the virologic effects of early therapy.

5 With early therapy (4 -9 hours postinfection) lysostaphin ste

6 apy initiation, thereby opening a window for early therapy adjustments.

7 Early therapy after onset of hyperglycemia and complete

8 e on the basis of recent trials showing that early therapy can be potentially beneficial to patients.

9 day 7 PET follow-up may be exploited toward early therapy change, especially for the 15% of patients

10 Early therapy consultation was a modifiable characterist

11 stratified by age at ART initiation (<3 mo, early therapy [ET]; >3 mo-2 years, late therapy [LT]) an

12 r cisplatin resistance, which often leads to early therapy failure or relapse.

13 ental etiology for AT and could advocate for early therapies for AT patients.

14 Hydroxychloroquine (HCQ) was proposed as an early therapy for coronavirus disease 2019 (COVID-19) af

15 nce interval, -1.83 to 4.32; P=0.42) for the early therapy group and 0.55 (95% confidence interval, -

16 d cellular infiltration and bone loss in the early therapy group, and reduced T cell proliferation in

17 single dose after collagen boost on day 21 (early therapy group, or as a single dose upon acquisitio

18 sease severity in the prophylactic group and early therapy group, reduced cellular infiltration and b

19 nts in the delayed-therapy group than in the early-therapy group (30 percent vs. 60 percent) had plas

20 linked transmissions, only 1 occurred in the early-therapy group (hazard ratio, 0.04; 95% CI, 0.01 to

21 f death of 69%, as compared with that in the early-therapy group (relative risk in the deferred-thera

22 bove each of the two thresholds of interest (early-therapy group) with that of patients who deferred

23 Subjects receiving early therapy had fewer treatment end points (hazard rat

24 This may be relevant for the timing of early therapy interventions in infants with pre- and per

25 nt to contain HCV replication, and also that early therapy is effective independent of such responses

26 ute to increased mortality, but nonselective early therapy may result in excess costs and drug resist

27 We would like to stress that early therapy might reverse the vessel complications.

28 nd initially elevated AFP, possibly enabling early therapy monitoring independent of morphology.

29 commodate immune escape, we hypothesize that early therapy of primary infection may be beneficial des

30 Early therapy of sepsis involving fluid resuscitation an

31 Additionally, the influence of early therapy on these responses and their relationships

32 e antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or th

33 y according to age--three months or younger (early therapy) or older than three months (delayed thera

34 SSTR TV decrease after C1 could be used for early therapy response assessment as a predictor of PRRT

35 Early therapy response evaluation was assessed by (99m)T

36 Methods: Early therapy response evaluation was assessed by (99m)T

37 n and escalation based on tumour biology and early therapy response.

38 ition, sPLA(2) may be useful for instituting early therapies to prevent or reduce the clinical morbid

39 ush macromolecules could be envisioned as an early therapy to preserve and protect viable muscle and

40 Early therapies treated most patients with asthma simila

41 We tested the hypothesis that early therapy with inhaled glucocorticoids would decreas

42 Early therapy with mTOR inhibitors offers effective, pat

43 Early therapy with neuraminidase (NA) inhibitors, either

44 Finally, an early therapy with purified human inter-alpha inhibitor

45 ding and emergence of escape mutations after early therapy with sotrovimab.

46 atients who are asymptomatic and instituting early therapy would improve neurologic outcome.